Briefly, the findings of this research showed that TRPV4 promoted cell death and inhibited migration as well as proliferation via the p38 MAPK pathway in human LC cell lines, indicating that TRPV4 could serve as a promising innovative target for the treatment of LC in the future. This evidence concerns the gene TRPV4 and laryngotracheoesophageal cleft.